tbuckley/cabot-search huggingface dataset:
A phase II feasibility study of preoperative chemotherapy with bevacizumab for resectable stage II/IIIA non-squamous non-small cell lung cancer.
Authors: Yoshihiro Miyata, Yasuhiro Tsutani, Kenji Suzuki, Kazuya Takamochi, Fumihiro Tanaka, Haruhiko Nakayama, Yoshinori Yamashita, Masahiro Tsuboi, Makoto Oda, Morihito Okada
Journal: Journal of Clinical Oncology (2015)

7552 Background: Bevacizumab (Bev) has been demonstrated to improve response and survival rates in patients with advanced non-small cell lung cancer (NSCLC). This phase II trial assessed the feasibility of the addition of Bev to preoperative chemotherapy in resectable non-squamous NSCLC. Methods: Patients with clinical stage II/IIIA non-squamous NSCLC were recruited from 6 institutions. Three cycles of cisplatin (Cis) (75 mg/m2), pemetrexed (Pem) (500 mg/m2), and Bev (15 mg/kg) were administered on day 1 and every 21 days thereafter, followed by surgical resection. The primary endpoint was the complete resection rate (CRR) after completion of 3 cycles of chemotherapy. The sample size was set at 30 patients. The treatment was considered feasible if the CRR was ≥ 80%. Results: Thirty patients were eligible. Grade 3 toxicities included neutropenia (7%), nausea (7%), hypertension (23%), and pulmonary embolism (3%). There were no grade 4 events, and 27 (90%) patients completed 3 cycles with full doses of chemotherapy. Twenty-nine patients (97%) exhibited radiologic tumor reduction. The objective responses to chemotherapy were as follows: complete response, 0%; partial response, 37%; stable disease, 50%; and progressive disease, 10%. Five patients dropped out from the study before surgery due to the patient's decision in one patient, adverse events in three and disease progression in one. Disease control and surgical eligibility was confirmed in 25 (83%) patients after completion of 3 cycles of induction chemotherapy. These patients underwent surgery, and all achieved complete resection (CRR after completing three cycles of induction chemotherapy, 83%). Neither grade 3/4 morbidity within 28 days after surgery nor treatment-related mortality within 84 days after surgery was observed. Conclusions: Preoperative chemotherapy with combined Cis, Pem, and Bev for clinical stage II/IIIA non-squamous NSCLC is considered feasible. These data provide further evidence that Bev may be used as a promising candidate for future randomized trial arm for patients with locally advanced NSCLC. Clinical trial information: UMIN000004278.
P-032 Selenium administration attenuates 5-fluorouracil induced intestinal mucositis
Authors: J.M. Lee, H.J. Chun, I.K. Yoo, S.H. Kim, H.S. Choi, E.S. Kim, B. Keum, Y.T. Jeen, H.S. Lee, C.D. Kim
Journal: Annals of Oncology (2015)
Putting health inequalities to music
Authors: Anne Gulland
Journal: BMJ (2016)

Ilan Kelman

Song of Contagion is a new musical project that aims to shed light on why some diseases get more attention than others.

The first session of the project, a collaboration between the Grand Union Orchestra, Community Music (an organisation encouraging children to get involved in digital music), and the epidemiologist Elizabeth Pisani, was held on 23 April in London. Musicians and …
TCTAP C-101 Successful Recanalization of Very Long Duration Chronic Total Occlusion in Right Coronary Artery by Using the Retrograde Approach via Occluded Saphenous Vein Graft
Authors: Yasushi Ino, Takashi Kubo, Yosuke Katayama, Yoshiki Matsuo, Hironori Kitabata, Yasunori Yamamoto, Takeyoshi Kameyama, Takashi Yamano, Tomoyuki Yamaguchi, Makoto Orii, Hiroshi Aoki, Atsushi Tanaka, Takeshi Hozumi, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2016)
A humanized microbiota mouse model of ovalbumin-induced lung inflammation
Authors: Marie-Claire Arrieta, Manish Sadarangani, Eric M. Brown, Shannon L. Russell, Michael Nimmo, John Dean, Stuart E. Turvey, Edmond S. Chan, B. Brett Finlay
Journal: Gut Microbes (2016)

There is increasing evidence for a role of early life gut microbiota in later development of asthma in children. In our recent study, children with reduced abundance of the bacterial genera Lachnospira, Veillonella, Faecalibacterium, and Rothia had an increased risk of development of asthma and addition of these bacteria in a humanized mouse model reduced airway inflammation. In this Addendum, we provide additional data on the use of a humanized gut microbiota mouse model to study the development of asthma in children, highlighting the differences in immune development between germ-free mice colonized with human microbes compared to those colonized with mouse gut microbiota. We also demonstrate that there is no association between the composition of the gut microbiota in older children and the diagnosis of asthma, further suggesting the importance of the gut microbiota-immune system axis in the first 3 months of life.
Amrubicin Monotherapy in Patients with Platinum-Refractory Metastatic Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma of the Gastrointestinal Tract
Authors: T. Araki, T. Hamaguchi, A. Takashima, Y. Honma, S. Iwasa, N. Okita, K. Kato, Y. Yamada, H. Hashimoto, H. Taniguchi, R. Kushima, K. Nakao, Y. Shimada
Journal: Annals of Oncology (2014)
The Association Between Atrophy and the Prognosis of Anti-<i>N</i>-Methyl-<scp>d</scp>-Aspartate Receptor Encephalitis
Authors: Maarten J. Titulaer
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
Authors: Matthew H. G. Katz, Qian Shi, Syed A. Ahmad, Joseph M. Herman, Robert de Wilton Marsh, Eric Andrew Collisson, Lawrence H. Schwartz, Robert C. G. Martin, William Charles Conway, Mark Truty, Hedy Lee Kindler, Andrew M. Lowy, Philip Agop Philip, Tanios S. Bekaii-Saab, Dana Backlund Cardin, Noelle K. LoConte, Alan P. Venook
Journal: Journal of Clinical Oncology (2015)

4008 Background: Infusional 5-FU, oxaliplatin, leucovorin and irinotecan (FOLFIRINOX) is effective for metastatic PDAC. The tolerability and efficacy of neoadjuvant FOLFIRINOX and CRT for BLR PDAC is unknown. Methods: Patients (pts) with ECOG PS 0/1 and PDAC meeting any of the following centrally-reviewed radiographic criteria: 1) tumor-vessel interface (TVI) with superior mesenteric/portal vein (SMV) ≥ 180°, 2) TVI with superior mesenteric artery (SMA) < 180°, 3) TVI with hepatic artery of any degree, received mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2 on day 1 followed by 5-FU 2400 mg/m2 x 48 hours for 4 cycles) and CRT (50.4 Gy in 28 fractions) with capecitabine (825mg/m2 BID) prior to pancreatectomy and postoperative gemcitabine (1000 mg/m2 d1, 8,15 x 2 cycles). Results: 22 of 23 enrolled pts started therapy (median age 64 years, 64% ECOG PS 0). All pts completed mFOLFIRINOX and 21 (95%) completed CRT. The best RECIST responses during pre-op treatment were 2 CR, 4 PR, 15 SD and 1 PD. 7 patients did not undergo planned resection due either to progression (6) or refusal (1). Among the 15 (68%) patients who did undergo pancreatectomy, 14 (93%) operations were R0; 80% and 27% of operations required vein or hepatic artery resection, respectively; 7 (47%) specimens had < 5% residual tumor cells following therapy. Among all pts, 68% [95% CI (45.1 – 86.4)] underwent R0/R1 resections and 2 (9%) achieved pathologic CR. Related grade III and IV adverse events were observed in 46% (10 of 22) and 5% (1 of 22) of pts during chemotherapy, 38% (8 of 21) and 0% during CRT, and 15% (2 of 13) and 31% (5 of 13) following pancreatectomy; 1 pt died within 90 days of surgery. 18 pts are alive with an immature median follow-up of 10 months. Conclusions: In this multi-institutional study of pts with PDAC tumors that had a substantial radiographic interface with the SMV, SMA or hepatic artery, mFOLFIRINOX and CRT was associated with manageable toxicity that did not preclude subsequent resection. Although a RECIST response was uncommon, the efficacy of this preoperative regimen is suggested by high rates of R0 resection and pathologic response. Clinical trial information: NCT01821612.
Case 13-1964
Authors: Malcolm M. Hargraves, Austin L. Vickery
Journal: New England Journal of Medicine (1964)

Presentation of Case*A sixty-year-old woman entered the hospital because of skin lesions.She had been in good health until two years before admission, when she began to lose interest in activities and became aware of gradually progressing muscular weakness. Previously a vigorous walker, she had to limit her activity to the vicinity of her house. The weakness also involved chewing and swallowing movements. Except for slight numbness of the toes she noticed no sensory abnormality. She was anorectic and lost 30 pounds in weight. One year before admission pustular lesions appeared in the right groin. They improved with local . . .
Soundings: Luvvies’ guide
Authors: James Owen Drife
Journal: BMJ (1999)

Damon Seerewijf is a renaissance doctor. His exhibition of abstract medical art opened recently at the Galerie La Vage in Paris, but his day job is professor of molecular umbiloscopy at the University of Palm Beach. Author of more than 200 papers and a syndicated column, he recently converted to Buddhism.

Who was your most influential teacher? Hippocrates. Everybody knows his name, but only a few of us have read him in the original Greek. I love his sly sense of irony.

Which event has had most effect on your work? The birth of my daughter. Suddenly, life clicked. I think of that moment every time I email a paper to a journal. And I take the video whenever I travel.

What would be your advice to a newly qualified doctor? Forget everything they taught you. Look, live, paint, weep, think.

How do you relax? I swim with a friend who happens to be a dolphin.

What is your favourite film? “A night at the opera.” I see myself as a fusion of Groucho and Harpo, while Margaret Dumont personifies the medical establishment.

What is your greatest fear? Losing my humility.

What are you currently reading? Nietzsche’s Die Geburt der Tragodie, Unzeitgemasse Betrachtungen and Menschliches, Allzumenschliches.

What is your greatest regret? Not learning German.

What alternative therapies have you tried? Did they work? I regularly practise yoga but I see it as mainstream. For me, aspirin is alternative. I tried it and it didn’t work.

What is the greatest love of your life? After my daughter, the Angkor Wat in Cambodia—its serenity started me on the road to Zen. My wife will kill me for that answer but I’ll be reincarnated as her husband.

What is your worst habit? Quoting too much from Jackson Pollock when I lecture on molecular medicine. Audiences just don’t get it.

How would you like to die? There’s no need to threaten me. If you don’t like pretentiousness just turn the page.
Concentrations of Lead in Bone in Plumbism
Authors: Maxwell P. Westerman, Emil Pfitzer, Lawrence D. Ellis, Wallace N. Jensen
Journal: New England Journal of Medicine (1965)

DESCRIPTIONS of lead poisoning include repeated observations that persons or animals with apparently similar exposure may have different degrees of severity of symptoms. The ability to make accurate measurements of lead concentrations in the environment, body tissues and fluids has provided more precise means for examining the relation between the development of symptoms and the exposure to lead. The simple semiquantitative methods for the detection of certain intermediate compounds of porphyrin or heme synthesis that are present in increased amounts in the tissues or excreta in plumbism indicate biologic abnormality in lead exposure. The differentiation of lead exposure and lead . . .
Structure, Functional Changes, and Proliferative Pathology of the Human Mammary Lobule in Cancerous Breasts<xref ref-type="fn" rid="FN2">2</xref>
Authors: F Squartinl, R Sarnell
Journal: JNCI Journal of the National Cancer Institute (1981)

The mammary glandular tree of 50 human female breasts removed for clinical cancer by radical mastectomy was studied by subgross analysis in whole thin slices, a method that allowed a three-dimensional appraisal of the glandular structures, with removal of interesting or suspicious changes for histology. The glandular tree was more often atrophic (70%) than "adenosic" (righ in mammary lobules, 30%). Many physiopathologic changes were observed, mainly in the lobular area. Abnormal lobules were categorized by type on the basis of size, sensitivity to hormones, stroma, architecture, pattern of epithelial proliferation, cell type, and cell grading. The functional and minor lobular changes (atrophic, sclerotic, hyperplastic, and cystic) were frequent and, as expected, unevenly distributed between adenosic and atrophic breasts. The proliferative lobular changes (including atypical lobules with epithelial proliferation and metaplastic or apocrine lobules with epithelial proliferation) were also frequent but evenly distributed in adenosic (51%) or atrophic (46%) breasts. Intrinsic or extrinsic epithelial proliferation often caused unfolding or lengthening of the lobular structures with deviation of lobular architecture toward ductlike formations. The cells of proliferative changes ranged from typical cells to the anaplastic cells of in situ carcinomas. Independent microscopic foci of infiltrating cancer were found in 20% of either adenosic or atrophic breasts.
Abstract 4870: GenePool: A cloud-based technology for rapidly data mining large-scale, patient-derived cancer genomic cohorts including The Cancer Genome Atlas
Authors: Sandeep Sanga, Antoaneta Vladimirova, Richard D. Goold, Tod M. Klingler
Journal: Cancer Research (2015)

Abstract GenePool is a cloud-based system for the secure storage, management, analysis, visualization and interpretation of large-scale human genomics data. The GenePool platform enables rapid interrogation of massive amounts of data generated by current laboratory methods and was designed to meet the needs of scientists engaged in cancer biomarker discovery and characterization. The software solution provides users with an intuitive interface, an easy way to store and select genomics datasets according to sample-associated metadata for analysis, and an automated system for performing routine, well-characterized genomics workflows. Results are presented with multiple options for annotation, sorting and data export, with a visualization tool that facilitates browsing of genomic data for biomarker identification. We will demonstrate how GenePool removes the data download, management, and computing burdens faced by researchers interested in working with large amounts of patient-derived cancer genomics exemplified by The Cancer Genome Atlas. To date, TCGA has completed molecular characterization of more than 9,000 patient samples from a target of 17,000, and will have released an estimated 2.5 petabytes of data at project completion. We will present case studies using the &amp;gt;25 cancer cohorts worth of RNA-Seq, miRNA-Seq, Exome Sequencing, Protein Expression, Copy Number, and DNA Methylation data (provided to the community through the TCGA Data Portal) and made readily available for sample selection and analysis within GenePool. As validation of the GenePool platform, we will present results obtained within minutes that validate knowledge reported in the literature over the course of decades. We will then present novel findings for less understood cancer indications. Note: This abstract was not presented at the meeting. Citation Format: Sandeep Sanga, Antoaneta Vladimirova, Richard D. Goold, Tod M. Klingler. GenePool: A cloud-based technology for rapidly data mining large-scale, patient-derived cancer genomic cohorts including The Cancer Genome Atlas. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4870. doi:10.1158/1538-7445.AM2015-4870
A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells
Authors: Xiaoli Wang, David Haylock, Cing Siang Hu, Wioleta Kowalczyk, Tianbo Jiang, Jiajing Qiu, Goar Mosoyan, Wu He, Netonia Marshall, John Mascarenhas, Anna Tarasova, Joshua Brody, David Winkler, Ronald Hoffman
Journal: Blood (2016)
Spontaneous perforation of an intramural esophageal pseudodiverticulosis treated with intraluminal endoscopic vacuum therapy using a double-lumen vacuum drainage with intestinal feeding tube
Authors: Josef Aumiller, Frank Rucktäschel, Tobias Schorsch, Gunnar Loske
Journal: Endoscopy (2016)

An intraluminal variant of endoscopic vacuum therapy (EVT) [1] [2] was used in a case of acute spontaneous perforation of the esophagus. To enable simultaneous enteral nutrition, a double-lumen vacuum drainage with intestinal feeding tube was constructed.
Novel formulation of RNase and DNAse employing unique nanospheres to allow oral drug delivery and demonstrate anticancer activity.
Authors: Amichay Meirovitz, Hovav Nechushtan, Alexander Vol, Orna Gribove, Hanna Levi, Hadas Gantz-Sorotsky, Shai Efrati
Journal: Journal of Clinical Oncology (2015)

e18546 Background: RNase has been used previously for anticancer therapy and has demonstrated some activity mainly in mesothelioma patients. In cancer models DNAse has also demonstrated anticancer activity. A possible limitation of the current I.V. delivered enzymes is their relatively limited half-life. We have therefor used a novel nanoparticle based therapy which allows oral protein delivery for these drugs. Methods: We used colonies of mice with Tumor graft (Champions TumorGrafts model) obtained from lung cancer patients. Nano spheres loaded with DNAse and RNAse (Oshadi D and R) were used alone or as an addition to chemotherapy to treat these mice. Later 4 patients harboring progressive mesothelioma were compassionately treated by with a similar formulation. Results: Treatment of mice harboring 4 different tumor graft demonstrated significant activity of the Oshadi D and R formulation alone. Furthermore in the 3 models tested for effect of the combination of Oshadi D and R with standard chemotherapy there was an additive effect of this formulation when delivered orally to the chemotherapeutic effect. The progression free survival duration of the three patients that were treated only with Oshadi D and R was 14 to 18 months. During the treatment patients had active life with improved quality of life. A fourth patient treated with Oshadi D and R combined with reduced dose of Pemetrexed continues treatment with a good quality of life (already 30 months). Conclusions: The results are intriguing and suggest that the use of oral delivery nuclease has a potential in cancer treatments. We have therefore initiated phase II trials for NSCLC and mesothelioma. Clinical trial information: NCT01201018.
Comprehensive Genetic Analyses Of 213 PMF Patients Revealed 13% Of SRSF2 Mutations Being Strongly Correlated To ASXL1 Mutations
Authors: Manja Meggendorfer, Tamara Alpermann, Christiane Eder, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger
Journal: Blood (2013)
Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer
Authors: J. Dunst, T. Reese, J. Debus, T. Hoelscher, W. Budach, V. Rudat, J. Wulf, S. Mose, A. Hinke
Journal: Journal of Clinical Oncology (2004)

3559 Purpose: A recent phase-I-study demonstrated that capecitabine (Xeloda) can safely be combined with pelvic radiotherapy in patients with rectal cancer (Dunst et al, JCO 2002). We conducted a phase-II-study for to confirm safety and efficacy of chemoradiation with Xeoda as preoperative therapy in locally advanced rectal cancers. Patients & methods: 98 patients (median age 65 years, range 34 - 81years) with advanced rectal cancers (cT3–4 or extensive nodal involvement) were recruited from 7 centers in the period from 6/2001 through 11/2003. Therapy consisted of preoperative chemoradiation (50.4Gy in 28 fractions + 5.4Gy boost, Xeloda 825mg/m2 b.i.d. from first to last day of radiotherapy) followed by surgery 6 weeks later. At the time of this analysis (Dec-2003), 58 patients have completed therapy and are evaluable for baseline characteristics and toxicity (N=58) as well as clinical (N=49) and pathological response (N=50). All patients had advanced disease (cT4: 50%, cT3: 48%, cT2: 2%, cN+: 55%). Results: Chemoradiation with Xeloda was well tolerated with no or mild to moderate toxicity in the vast majority of patients. No treatment-related grade 4-toxicity was observed (except a period of hyperglycemia in a patient with diabetes). Main grade 3 toxicities included leuko- and lymphopenia (10%), diarrhea (4%), hypopotassemia (4%) as well as local skin erythema in the radiation fields, bilirubin increase, hypocalcemia and hyponatremia (each in 1 pat.). Clinical response (evaluated 6 weeks after chemoradiation) was observed in 30/49 patients with 28 cPR (57%) and 2 cCR (4%). All patients underwent surgery with 46 R0-resections (92%) and 4 R1-resections (8%). Downstaging of the primary tumor (cT < pT) occurred in 37 pats (74%). A pCR was observed in 2 patients (4%) with 1 additonal case with only pTis in the resection specimen (2%). Conclusions: This phase-II study confirmed that Xeloda is an adequate substitute for continuous infusional 5-FU in preoperative chemoradiation regimens with regard to the favorable toxicity profile and response. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Roche